X-ZELL is fusing next-generation cell detection technology with cutting-edge Artificial Intelligence to isolate and visualise ultra-rare cells in blood and frozen tissue. Established in Bangkok, Thailand, the company recently made global headlines for successfully isolating and visualising tumour-associated Circulating Endothelial Cells (tCEC) from the blood of high-risk prostate cancer patients. Long considered undetectable in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancers early, when they can be cured – in turn avoiding more than 70 per cent of unnecessary interventions and saving billions to health systems worldwide. X-ZELL is aiming to make tCEC-based cancer screening accessible to patients around the globe – making the young company one of the promising names in the booming cancer prevention space.

X-Zell

X-Zell